Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A panel of federal health experts on Wednesday recommended expanded vaccine options for several diseases, including ...

A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

A minor’s ability to legally consent on their ... people receive the HPV vaccine around ages 11-12 to prevent the risk of sexually transmitted diseases and multiple forms of cancer, including ...

disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published online April 1 in JAMA Network Open. Diya Surie, M.D., from the U.S. Centers for Disease ...

78.5 percent of unvaccinated adults are unsure if they were eligible for vaccination or thought they were not ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults, according to a study published online April 1 in JAMA Network Open.

Respiratory syncytial virus was linked to elevated incidence of cardiovascular events in older adults. Future research will help decide whether vaccination could reduce the impact of RSV on the heart.

Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscular as a single 0.8mL dose. Vimkunya ™ (chikungunya vaccine, recombinant) is now available in the US for the ...

A 2023–24 vaccine effectiveness analysis of immunocompetent adults aged 60 years or older in the USA showed 80% (95% CI 71–85) protection against respiratory syncytial virus (RSV)-associated hospital ...